Brief: Intelligent Bio Begins Subject Dosing And Sampling For Drug Screening Technology Study
18/06/2024 14:25
June 18 (Reuters) - Intelligent Bio Solutions Inc
INBS.O :
* INTELLIGENT BIO SOLUTIONS BEGINS SUBJECT DOSING AND
SAMPLING FOR
FDA 510(K) PHARMACOKINETIC (PK) STUDY FOR ITS INTELLIGENT
FINGERPRINTING DRUG SCREENING TECHNOLOGY
* INTELLIGENT BIO SOLUTIONS INC - INBS PLANS 510(K) FDA
SUBMISSION
IN Q4
* INTELLIGENT BIO SOLUTIONS INC - AIMS TO COMPLETE DOSING BY
END
OF JUNE 2024
Source text for Eikon: ID:nGNX6MnWnS
Further company coverage: INBS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Intelligent Bio Solutions
See all newsBrief: Intelligent Bio Solutions Reports Fiscal 2026 Full-Year Revenue Growth Of 38% Year-Over-Year, Driven By Reader Installed Base And High-Margin Cartridge Growth
Brief: Intelligent Bio Solutions Initiates Clinical Study Supporting FDA Clearance And Planned US Market Entry
Intelligent Bio Solutions Q3 revenue rises 46%, gross margin tops 50%
Intelligent Bio Solutions rise after clearing security tests ahead of FDA filing
Brief: Intelligent Bio Solutions Completes Clinical Cut-Off Study